OptimizeRx Corporation has reported its financial results for the first quarter of 2025, revealing a notable performance. The company's revenue in Q1 2025 increased by 11% year-over-year, reaching $21.9 million, compared to $19.7 million in the same period of the previous year. Gross profit for the quarter also saw an increase of 9% year-over-year, amounting to $13.3 million. The company reported an improvement in adjusted EBITDA, which rose to $1.5 million in the first quarter of 2025, compared to a loss of $0.3 million in the same quarter of the prior year. OptimizeRx's cash, cash equivalents, and short-term investments totaled $16.6 million as of March 31, 2025, up from $13.4 million as of December 31, 2024. In light of these results, OptimizeRx has updated its full-year 2025 guidance, now forecasting revenue to be in the range of $101 million to $106 million, with adjusted EBITDA expected to fall between $13 million and $15 million. Stephen L. Silvestro, CEO of OptimizeRx, expressed optimism about the company's performance, citing a more than 20% increase in year-to-date contracted revenue compared to the same period last year, which positions the company well for a strong second half of the year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.